In a phase II clinical trial, administration of sunitinib with DCs co-electroporated with amplified tumor and synthetic CD40L mRNA yielded supportive immune responses and extension of long-term survival in 21 patients with advanced RCC (60). Here, CD40LG is linked to neoplasm.